/
© 2026 RiffOn. All rights reserved.

Get your free personalized podcast brief

We scan new podcasts and send you the top 5 insights daily.

  1. Research To Practice | Oncology Videos
  2. Low-Grade Serous Ovarian Cancer — Rapid Case Review: Microlearning Activity 2
Low-Grade Serous Ovarian Cancer — Rapid Case Review: Microlearning Activity 2

Low-Grade Serous Ovarian Cancer — Rapid Case Review: Microlearning Activity 2

Research To Practice | Oncology Videos · Sep 14, 2026

Experts discuss managing low-grade serous ovarian cancer, focusing on avutametinib/defactinib toxicities and treatment sequencing.

Avutametinib's Common CPK Elevation in Ovarian Cancer Is a Lab Finding, Not a Clinical Symptom

CPK elevation is a frequent lab finding with avutametinib but is almost always asymptomatic and doesn't cause clinical muscle weakness. This understanding has led to less stringent criteria for drug discontinuation, allowing more patients to remain on effective therapy despite the biomarker change.

Low-Grade Serous Ovarian Cancer — Rapid Case Review: Microlearning Activity 2 thumbnail

Low-Grade Serous Ovarian Cancer — Rapid Case Review: Microlearning Activity 2

Research To Practice | Oncology Videos·2 months ago

Ovarian Cancer Patients Can Respond to MEK Pathway Drugs Even After Progressing on a Prior MEK Inhibitor

A patient who failed trametinib later responded to the avutametinib/defactinib combination. This suggests that resistance to one MEK inhibitor does not preclude a response to a different agent or combination targeting the same pathway, offering a viable later-line treatment strategy.

Low-Grade Serous Ovarian Cancer — Rapid Case Review: Microlearning Activity 2 thumbnail

Low-Grade Serous Ovarian Cancer — Rapid Case Review: Microlearning Activity 2

Research To Practice | Oncology Videos·2 months ago

For Post-BRAF Inhibitor Progression in Ovarian Cancer, Appeal for KRAS-Targeted Drugs

For BRAF V600E low-grade serous ovarian cancer patients who progress on dabrafenib/trametinib, clinicians can appeal for the KRAS-approved combination avutametinib/defactinib. This strategy is based on evidence of the drug's activity in KRAS wild-type patients, offering a rational off-label option.

Low-Grade Serous Ovarian Cancer — Rapid Case Review: Microlearning Activity 2 thumbnail

Low-Grade Serous Ovarian Cancer — Rapid Case Review: Microlearning Activity 2

Research To Practice | Oncology Videos·2 months ago

Avutametinib/Defactinib Lacks the Congestive Heart Failure Risk Seen With the MEK Inhibitor Trametinib

While trametinib carries a ~6% risk of congestive heart failure, this specific toxicity has not been observed with the avutametinib/defactinib combination. This distinct safety profile makes the doublet a potentially safer option, especially for patients with cardiac risk or who failed trametinib due to heart issues.

Low-Grade Serous Ovarian Cancer — Rapid Case Review: Microlearning Activity 2 thumbnail

Low-Grade Serous Ovarian Cancer — Rapid Case Review: Microlearning Activity 2

Research To Practice | Oncology Videos·2 months ago

Prioritize Dose Holds Over Reductions for Effective Ovarian Cancer Drugs to Maintain Efficacy

When managing side effects from highly effective therapies like MEK inhibitors, it's often better to temporarily hold treatment and then resume at the original dose rather than immediately dose-reducing. This strategy maintains dose intensity, which is critical for maximizing the drug's therapeutic benefit.

Low-Grade Serous Ovarian Cancer — Rapid Case Review: Microlearning Activity 2 thumbnail

Low-Grade Serous Ovarian Cancer — Rapid Case Review: Microlearning Activity 2

Research To Practice | Oncology Videos·2 months ago